Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Rein Therapeutics, Inc. Director's Dealing 2020

Jun 18, 2020

34829_dirs_2020-06-18_76d8ec82-cf6b-4460-9c8f-e3803b38880a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2020-06-17

Reporting Person: MCKEE WILLIAM (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-06-17 Stock Option (right to buy) $1.15 A 12500 Acquired 2030-06-16 Common Stock (12500) Direct

Footnotes

F1: This option was granted on June 17, 2020. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 17, 2021 or (ii) the date of the Issuer's 2021 Annual Meeting of Stockholders.